Stocks · News reference
Glucotrack Completes Bridge Financing To Support Its Growth Plans
Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), together with its operating business Lōkahi Therapeutics™ ("Lōkahi"), a clinical-stage biopharmaceutical company advancing
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 17, 2026, 12:07 PM
- Checked
- Jul 17, 2026, 12:07 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
8-K filing — Glucotrack, Inc. (GCTK)
Filed: 2026-08-27 AccNo: 0001493152-26-040332 Size: 230 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgarGlucotrack Announces 1-For-15 Reverse Stock Split Effective August 31
Read original at benzingaGlucotrack's Lōkahi Therapeutic Subsidiary Initiates Good Manufacturing Practice Production Campaign For LT-100
Lōkahi Therapeutics™ Inc., a subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), today announced that it has started its initial Good Manufacturing Practice (GMP) manufacturing campaign for LT-100 (pure honeybee venom), the
Read original at benzinga